AbbVie (NYSE:ABBV) Stock Price Down 1.8% – What’s Next?

Shares of AbbVie Inc. (NYSE:ABBV) were down 1.8% on Thursday . The company traded as low as $257.25 and last traded at $258.2290. 4,329,557 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 6,784,919 shares. The stock had previously closed at $262.90.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for subcutaneous SKYRIZI induction in adults with moderately to severely active Crohn’s disease. If approved, the treatment would provide patients with an additional, less invasive induction option alongside the existing intravenous formulation. The filing is supported by positive Phase 3 AFFIRM data and could expand SKYRIZI’s European immunology opportunity. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: AbbVie continues to receive attention as a defensive healthcare company with a growing immunology pipeline. The company’s dividend profile is also being highlighted by income-focused investors, potentially supporting demand for the shares. 3 Dividend Stocks, 12 Paychecks a Year
• Positive Sentiment: Billionaire investor Ken Griffin reportedly increased his AbbVie stake by 547% in the second quarter, signaling continued institutional confidence in the company’s dividend and long-term earnings prospects. Ken Griffin Increased His Stake in AbbVie
• Neutral Sentiment: AbbVie’s immunology scholarship and patient-support initiatives enhance its corporate and patient engagement efforts, but they are unlikely to materially affect near-term earnings. AbbVie’s Immunology Scholarship Program
• Negative Sentiment: After a substantial advance, analysts are questioning whether AbbVie’s business can justify its premium valuation. The shares are near their 52-week high and carry a notably elevated reported price-to-earnings ratio, increasing the risk of profit-taking or valuation-driven weakness even as operating fundamentals remain solid. Has AbbVie Stock Become Too Expensive to Buy?

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ABBV shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $275.95.

AbbVie Price Performance

The stock has a market capitalization of $456.24 billion, a price-to-earnings ratio of 72.95, a PEG ratio of 0.88 and a beta of 0.30. The business’s fifty day moving average price is $251.04 and its 200-day moving average price is $228.43.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 195.48%.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Institutional Trading of AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Brighton Jones LLC boosted its position in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. raised its stake in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC boosted its holdings in shares of AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its holdings in shares of AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.